CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE

Post-LOE

ciprofloxacin hydrochloride and hydrocortisone

Novartis

ANDAOTICSUSPENSION/DROPS

Approved

Nov 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE (ciprofloxacin hydrochloride and hydrocortisone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for acute otitis externa in adult, one year, older and 3 more indications. First approved in 2025.

Drug data last refreshed 18h ago

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Indications (6)

acute otitis externa in adult one year older

Worked on CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.